FULGENT GENETICS, INC. (NASDAQ:FLGT) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition. |
On May 8, 2017, Fulgent Genetics, Inc. (the Company) issued a
press release announcing its financial results for the fiscal
quarter ended March 31, 2017. A copy of the Companys press
release containing this information is being furnished as Exhibit
99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Item 2.02, including Exhibit 99.1, shall not
be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, and shall not be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such a
filing.
|
Item 9.01. |
Financial Statements and Exhibits. |
|
(d) |
Exhibits. |
|
Exhibit No. |
Description |
|
99.1 |
Press Release of Fulgent Genetics, Inc., dated May 8, |
About FULGENT GENETICS, INC. (NASDAQ:FLGT)
Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company’s test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company’s gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers. FULGENT GENETICS, INC. (NASDAQ:FLGT) Recent Trading Information
FULGENT GENETICS, INC. (NASDAQ:FLGT) closed its last trading session up +0.09 at 10.71 with 12,812 shares trading hands.
